WIN Consortium to Use Foundation Medicine Test in 200-Patient Trial Starting 2013 | GenomeWeb

The Worldwide Innovative Networking Consortium in personalized cancer medicine plans to use Foundation Medicine's cancer genome profiling test in an upcoming clinical trial, the company said last week.

A company spokesperson told Clinical Sequencing News that the trial will involve 200 patients, who will be enrolled starting in early 2013. Each patient will be evaluated with the firm's sequencing-based test, FoundationOne, and be matched to a targeted therapy where possible.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.